Objective-To examine the association between genomewide association study-based diabetes mellitus-related singlenucleotide polymorphisms (SNPs) and coronary artery calcification (CAC), a valid risk factor for coronary heart disease, in a large, unselected, population-based cohort. Methods and Results-We genotyped 11 validated genomewide association study-based diabetes SNPs in 4459 participants of the Heinz Nixdorf Recall Study. We applied generalized linear regression models to explore the impact of the diabetes SNPs on CAC and to jointly model the effect of the SNPs and CAC on diabetes status. We observed a significant association between cyclin-dependent kinase inhibitor 2A/2B (CDKN2A/2B) variant rs564398 and quantitative CAC (Pϭ1.81ϫ10 Ϫ5 and adjusted Pϭ4.02ϫ10 Ϫ4 ; odds ratio for the presence of CAC, 1.12 [95% CI, 1.02 to 1.25]). Moreover, we observed no strong impact of CAC on diabetes risk in the presence of the other genetic variants. Conclusion-We show that a genetic variant near CDKN2A/2B that has been reported to be strongly associated with diabetes is strongly associated with CAC. In contrast, variants near insulin-like growth factor-binding protein 2 (IGFBP2), CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1), solute carreir family 30 (zinc transporter), member 8 (SLC30A8), hematopoietically-expressed homeobox (HHEX), and transcription factor 7-like2 (TCF7L2) were clearly associated with diabetes; no evidence for an association to CAC was observable. This differential association pattern underlines the potential of endophenotypes, such as CAC, to extend the scope of disease outcome associations.
T he development of both diabetes mellitus and subclinical atherosclerosis is characterized by a presumed early onset. 1 Prediabetic subjects have an atherogenic pattern of risk factors, possibly caused by obesity, hyperglycemia, and hyperinsulinemia, which may be present for many years before diabetes. 2 Moreover, elevated coronary artery calcification (CAC) has also been repeatedly observed in diabetes cases in both case-control and cohort studies 1,3-5 from the general population.
Because individuals with diabetes are at high risk for coronary heart disease, we were primarily interested in examining whether there is a genetic association between diabetes-related single-nucleotide polymorphisms (SNPs) derived for genomewide association studies (GWAS) 6 -11 and the extent of CAC in our population-based cohort study with 4459 unselected participants. As a secondary research question, we explored the known genetic association of the GWAS-based SNPs to diabetes as a clinical outcome in the presence or absence of CAC.
Methods

Study Population
We conducted a cross-sectional analysis among 4814 participants, aged 45 to 75 years, from the Heinz Nixdorf Recall (Risk Factors, Evaluation of Coronary Calcium, and Lifestyle) cohort. The participants were randomly selected from registration lists of the densely populated Ruhr metropolitan area in Germany (residents of Essen, Bochum, and Mü lheim) between December 2000 and August 2003. The rationale and design of the study were previously described in detail. 12 The baseline response of the study was 56%, 13 which is comparable to rates of other population-based studies. Information on genotypes, sex, age, CAC, and diabetes was available for up to 4459 of the 4814 participants ( Table 1 ). The study was approved by the local ethics committees and was conducted in accordance with the German Gute Epidemiologische Praxis, including extended quality management procedures and recertifications according to Deutsches Institut fü r Normung e.V. International Organization for Standardization (DIN ISO) 9001:2000. Informed consent was obtained from all participants.
The clinical outcome, diabetes (nϭ610), was defined as either of 4 criteria: (1) participants reported a history of diabetes, (2) participants took glucose-lowering drugs, (3) participants had fasting glucose levels of greater than 125 mg/dL, or (4) participants had nonfasting glucose levels of 200 mg/dL or greater. CAC was assessed by nonenhanced electron-beam computed tomographic scans (C-150 scanner; GE Imatron, San Francisco, Calif), as previously described. 3 Body mass index was calculated from standardized measurements of height and weight (weight in kilograms divided by height in meters squared), with participants in light underwear and without shoes. Table 1 presents the clinical characteristics of the study participants.
SNP Selection and Genetic Analyses
PubMed was searched for the keywords diabetes, SNP, CAC, polymorphism, GWAS, and replication between June 2008 and January 2009. Within this interval, 4 GWAS and several replication studies related to diabetes were published. 6 -11 The following SNPs (with the related genes and the minimum reported pairwise r 2 in parentheses) were selected using a threshold of PϽ10 Ϫ6 from the studies of Zeggini et al 10 and Steinthorsdottir et al 11 : rs4402960 (IGF2BP2), rs1801282 (peroxisome proliferator-activated receptor gamma [PPARG]), rs7754840, rs7756992, and rs10946398 (CDKAL1, r 2 Ͼ0.93), rs13266634 (SLC30A8), rs10811661 and rs564398 (CDKN2A/ 2B, r 2 Ͻ0.001), rs7903146 in TCF7L2 7 (r 2 ϭ0.94 with rs7901695), rs1111875 (HHEX, r 2 ϭ1 with rs5015480), and rs8050136 (fat mass and obesity associated [FTO] ). In addition, we also selected rs5219 potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11), but this SNP could not be included in the same genotyping assay and had to be omitted from this report.
Genotyping of all other SNPs in the population-based Heinz Nixdorf Recall Study was performed by matrix-assisted laser desorp-tion ionization-time of flight mass spectrometry-based iPLEX Gold assay at the Department of Genomics, Life and Brain Center, Bonn, Germany.
Statistical Analyses
The genotype distributions of all 11 SNPs were tested for deviations from the Hardy-Weinberg equilibrium (exact 2-sided PϾ0.05). All analyses were performed under a (log-) additive genetic model for each SNP, as suggested in the previous studies. 8, 9 First, we investigated the primary outcome, CAC, for an association to the GWAS-based SNPs (1) . Second, we checked the association of the validated GWAS-based SNPs to the clinical outcome, diabetes, in the presence or absence of CAC (2) . For the primary outcome, CAC, we performed 3 analyses (1a-1c). As the first analysis for the primary research question (1a), we used linear regression to analyze the untransformed quantitative CAC outcome in individuals for whom CAC was present (adjusted for sex, age, and diabetes status). This restriction was done to meet the normality assumption on which the modeling and the power consideration is based (as explained later). Next (1b), we used logistic regression for the binary CAC outcome (CAC Ͼ0 as presence of CAC and CACϭ0 as absence of CAC, adjusted for sex, age, and diabetes status). Finally, we used all available CAC data and addressed the marked right-skewed distribution of CAC by a log e transformation of CAC score plus 1, as previously suggested. 3 We applied linear regression to the transformed quantitative CAC outcome (adjusted for sex, age, and diabetes status; 1c). Because the conclusions for all these analyses were similar, we decided to limit the presentation to the analyses (1c) ( Table 2) .
To address the secondary research question (ie, the association of the validated GWAS-based SNPs to the clinical outcome, diabetes, in the presence or absence of CAC), we used logistic regression analyses adjusted for sex and age with and without log e -transformed CAC ( Table 3 ). In a last step, we also explored the impact of the dependency between the GWAS-based SNPs (related to 8 genes) and the other covariates on each of the 2 outcomes (CAC and diabetes) using backward selection for all predictors.
To our knowledge, because an association of the SNP to CAC has not been demonstrated previously, we decided to control the familywise error rate of the primary research question relating the SNPs to CAC at ␣ϭ5%. Consequently, we corrected for 11 SNPs/ statistical tests that translate into ␣ BF Ϸ0.005 using the Bonferroni procedure. For the primary analysis, we also performed power calculations using QUANTO Version 1.2.3 (http://hydra.usc.edu/gxe) for common variants, assuming a minor allele frequency of 7.5%, which is the smallest minor allele frequency of all explored SNPs, as based on the HapMap-Utah residents with Northern and Western European ancestry (CEU) samples (http://www.hapmap.org) and ␣ϭ0.005 (2sided) . For a sample of 3130 individuals (those with CAC Ͼ0 mean, 336.20; SD, 715.30), the comparisonwise power estimate was 91% (or 24%) assuming a standard normally distributed quantitative trait locus and standardized effect sizes of 0.2 (or 0.1) in SDs for each risk allele under an additive mode of inheritance without dominance effects. Thus, our study was well powered to detect relatively strong effect sizes of CAC-predisposing variants when controlling for multiple testing.
In addition, we determined 95% CIs for all estimates and report nominal 2-sided probability values that are not adjusted for multiple testing (unless otherwise stated). Table 2 shows the effect size estimators (␤s) for the linear regression models with quantitative transformed CAC (log e [CAC score ϩ1]) for 11 genetic markers related to 8 GWAS-based confirmed diabetes candidate genes. The marker rs564398 (CDKN2A/2B) was the only marker that showed an association to quantitative CAC with a significant online at http://atvb.ahajournals.org). We also stratified the sample by diabetes status and found similar effect size estimators for rs564398 and transformed CAC (␤ with diabetes ϭ Ϫ.18 and ␤ without diabetes ϭϪ. 20) . Supplemental Table II summarizes the genotype distribution of the CDKN2A/2B rs564398 by dichotomized CAC and diabetes status. Clearly, even in the absence of diabetes, the effect of rs564398 on CAC is still present. Finally, we explored the association of this particular marker (rs564398) with coronary heart disease as the result of reports on nearby coronary heart disease markers 14 (eg, rs4977574, which is 69 kb downstream of rs564398 (database SNP 36.3), with an r 2 of 0.27 between the markers; HapMap CEU release 22). We observed a crude odds ratio of rs564398 of 0.90 (95% CI, 0.76 -1.08; Pϭ0.27) for each G allele, which changed to an odds ratio of rs564398 of 0.88 (95% CI, 0.74 -1.06; Pϭ0.18) after adjustment for sex and age using logistic regression. Table 3 shows the association of the 11 GWAS-based diabetes SNPs with diabetes in the presence or absence of CAC. We found the strongest effect sizes for markers related to IGF2BP2, CDKAL1, SLC30A8, HHEX, and TCF7L2. When CAC was included in this model, the point estimators were not altered by more than 0.04. Finally, exploring the impact of sex, age, CAC, and the 9 SNPs related to 8 genes, again the same 4 of 5 diabetes-associated SNPs contributed independently to diabetes risk in addition to age, sex, and CAC (Table 3 ).
Results
Genetic Associations to CAC
Genetic Associations to Diabetes in the Presence or Absence of CAC as a Risk Factor for Diabetes
Discussion
The results of our study show the impact of the GWAS-based diabetes SNPs on the outcome of CAC and the joint relationship of these SNPs and CAC on the outcome of diabetes. We observed a significant association between rs564398 (CDKN2A/2B) and CAC. This association was significant after conservatively controlling for multiple testing by the Bonferroni method. Moreover, rs564398 (CDKN2A/2B) remained an independent predictor of CAC even after adjusting for sex, age, and diabetes status or all other diabetes markers in the multiple regression model. Moreover, we observed that the association of rs564398 (CDKN2A/2B) with CAC was largely because of stronger effects in males. In contrast to the problems that have been reported when testing for sex-specific effects, 15 we expected to see such sex differences given the larger load of CAC in males. 16, 17 However, follow-up studies are necessary to confirm our CAC findings.
With regard to the secondary research question (ie, the impact of the genetic markers on diabetes risk in the presence or absence of CAC), we replicated the diabetes association of risk alleles reported in the literature for 5 SNPs, rs4402960 (IGF2BP2), rs7756992 (CDKAL1), rs13266634 (SLC30A8), rs1111875 (HHEX), and rs7903146 (TCF7L2), in an unselected population-based cohort at a nominal ␣ level of 5%. 6 -10 All other SNPs showed directionally consistent effects when compared with those reported in the literature 6 -10,18 -20 (PϽ0.001 for a binomial test). Except for rs564398, the point estimates for diabetes risk of all investigated SNPs did not vary much after including CAC in the model.
The marker rs564398 is located approximately 100 kb 5Ј of gene CDKN2A/2B. CDKN2A and CDKN2B encode the prototypic tumor suppressor protein (INK)-4 proteins p16INK4a and p15INK4b, respectively, which play an important role in the regulation of the cell cycle, ␤-cell proliferation, and transforming growth factor ␤-induced growth inhibition. [21] [22] [23] Through transforming growth factor ␤/Smaand Mad-related protein signaling, this region may be implicated in the pathogenesis of atherosclerosis. 21 Recently, it was shown that ANRIL (another predicted gene within the 9p21 region) expression is associated with atherosclerosis and 9p21 region SNPs. 24 To summarize, the 9p21 region has been strongly associated with susceptibility to coronary artery disease, myocardial infarction (to other largely independent markers, such as rs4977574), and diabetes (in particular rs564398), suggesting the possibility of a shared mechanism causing subclinical atherosclerosis, coronary artery disease, and diabetes. 7, 8, 10, [25] [26] [27] In the light of our results, however, functional or animal studies should focus on atherosclerotic phenotypes first and might benefit from including sex information as well.
However, this study also has some limitations. In light of emerging GWAS meta-analyses, a sample size of approximately 4400 individuals is relatively limited with regard to statistical power to confirm the reported diabetes associations. As a consequence, this study focused on CAC and a particular set of GWAS-based diabetes markers attenuating the multiplicity problem. Furthermore, our population-based cohort has not been included in any of the GWAS detection meta-analyses. Thus, we were able to take an independent look at the available evidence. Another limitation is the selection of GWAS-based diabetes markers, given that the recent review already described 19 genomic loci related to diabetes status. 28 Thus, our investigation of CAC and its relationship to diabetes is not comprehensive. On the other hand, the effects on diabetes risk are even smaller for the new markers, most likely leading to even more pronounced power problems for our analyses. Some of these issues may become addressable once genotype data for the Metabochip (designed for fine mapping to follow up on findings from several large-scale consortia, such as CARDIoGRAM (Coronary ARtery DIsease Genome-wide Replication And Meta-Analysis), DIAGRAM (Diabetes Genetics Replication And Meta-analysis Consortium), GIANT (Genomewide Investigation of ANThropometric measures), MAGIC (Meta-Analysis of Glucose and Insulin-related traits Consortium), Lipids (Genome-wide association study of Lipids), ICBP-GWAS (Genome-wide association study of blood pressure), and QT-IGC (Genome-wide association study for QT interval) become available for the Heinz Nixdorf Recall Study cohort.
In conclusion, we provide evidence for an association of rs564398 near CDKN2A/2B to CAC. Thus, this genetic locus is more likely related to subclinical atherosclerotic processes and to diabetes as a secondary phenomenon. We further substantiate that genetic variation in IGF2BP2, CDKAL1, SLC30A8, HHEX, and TCF7L2 is associated with diabetes and largely independent of subclinical atherosclerotic pro-cesses. By investigating the effects of GWAS-based diabetes SNPs of likely functional relevance and the burden of CAC in an unselected central European population, we underline the potential of using (endo)phenotypes, such as CAC, to address yet unknown properties of the genetic markers from a genetic-epidemiological point of view.
